Paratek Pharmaceuticals (PRTK) Doses First Patient in Phase 3 Study of Oral-only Omadacycline in ABSSSI
Tweet Send to a Friend
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today the dosing of the first patient in its second pivotal Phase 3 study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
